Quick FactsSomeone in the world is newly infected with tuberculosis every second.
Our strategy is to leverage our experience in handling highly hazardous microorganisms, our expertise in therapeutic development, our >150,000 proprietary compound library of small molecules and natural product new chemical entities (NCE), and targeted in-licensing opportunities to advance the development of promising new antibiotics in infectious diseases.
We believe our products have clinical and commercial potential that will capture a significant market opportunity in anti-infectives. The principal elements of our strategy are to:
Broaden our competitive strengths in working with infectious agents to develop superior therapeutic products for treatment of other underserved infectious diseases;
Partner with pharmaceutical and biotechnology companies, as well as academic institutions and governmental organizations, to accelerate product commercialization and to defray the cost of product development;
Complete proof-of-principle Phase 2 clinical development of our leading anti-infectives to create additional value and enhance our ability to partner; and
Monetize our non-core assets to provide additional funding for our anti-infectives development programs.